Literature DB >> 7893591

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.

L Bertilsson1, J A Carrillo, M L Dahl, A Llerena, C Alm, U Bondesson, L Lindström, I Rodriguez de la Rubia, S Ramos, J Benitez.   

Abstract

In a previous study we showed that the disposition of clozapine after a single oral dose is unrelated to either debrisoquine or S-mephenytoin hydroxylation polymorphism. The same 14 healthy subjects studied in that investigation were given 150 mg of caffeine. The reciprocal of plasma clozapine AUC (0,24), was correlated with an index of the N3-demethylation of caffeine (rs = 0.84; P = 0.0024), used as a measure of cytochrome P4501A2 (CYP1A2) activity. N1- and N7-demethylation indices of caffeine also reflect CYP1A2 activity and were also correlated with clozapine clearance (rs = 0.89 and 0.85; P = 0.0013 and 0.0023; respectively). No significant relationships with xanthine oxidase and N-acetyl transferase activity, also assessed by a caffeine test, were found. This study suggests that clozapine is metabolised by CYP1A2 to a major extent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7893591      PMCID: PMC1364883          DOI: 10.1111/j.1365-2125.1994.tb04385.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Interaction between fluvoxamine and imipramine/desipramine in four patients.

Authors:  E Spina; G M Campo; A Avenoso; M A Pollicino; A P Caputi
Journal:  Ther Drug Monit       Date:  1992-06       Impact factor: 3.681

2.  Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.

Authors:  C von Bahr; G Movin; C Nordin; A Lidén; M Hammarlund-Udenaes; A Hedberg; H Ring; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1991-03       Impact factor: 6.875

Review 3.  Clozapine. A novel antipsychotic agent.

Authors:  R J Baldessarini; F R Frankenburg
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

4.  Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans.

Authors:  M L Dahl; B Ekqvist; J Widén; L Bertilsson
Journal:  Acta Psychiatr Scand       Date:  1991-07       Impact factor: 6.392

5.  Fluvoxamine-tricyclic antidepressant interaction. An accidental finding.

Authors:  G Bertschy; S Vandel; B Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.

Authors:  A Llerena; C Alm; M L Dahl; B Ekqvist; L Bertilsson
Journal:  Ther Drug Monit       Date:  1992-04       Impact factor: 3.681

7.  Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.

Authors:  M L Dahl-Puustinen; A Lidén; C Alm; C Nordin; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

8.  Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age.

Authors:  C Haring; U Meise; C Humpel; A Saria; W W Fleischhacker; H Hinterhuber
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

Authors:  L Bertilsson; A Aberg-Wistedt
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

10.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

Authors:  K Brøsen; E Skjelbo; B B Rasmussen; H E Poulsen; S Loft
Journal:  Biochem Pharmacol       Date:  1993-03-24       Impact factor: 5.858

View more
  43 in total

1.  Effect of caffeine on clozapine pharmacokinetics in healthy volunteers.

Authors:  S Hägg; O Spigset; T Mjörndal; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

2.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women.

Authors:  Anna Nordmark; Stefan Lundgren; Birgitta Ask; Fredrik Granath; Anders Rane
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

3.  Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo.

Authors:  J T Larsen; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

4.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

Review 5.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

6.  BJCP 40th anniversary: moving forward, looking back.

Authors:  Annette Gilchrist; Yoon K Loke; Andrew A Somogyi; Adam F Cohen; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

Review 7.  Therapeutic drug monitoring for tomorrow.

Authors:  Erik Eliasson; Jonatan D Lindh; Rickard E Malmström; Olof Beck; Marja-Liisa Dahl
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

Review 8.  Clozapine plasma level monitoring: current status.

Authors:  T B Cooper
Journal:  Psychiatr Q       Date:  1996

Review 9.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2.

Authors:  K Brøsen
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

10.  Identification of a novel splice-site mutation in the CYP1A2 gene.

Authors:  Delphine Allorge; Dany Chevalier; Jean-Marc Lo-Guidice; Christelle Cauffiez; Françoise Suard; Pierre Baumann; Chin B Eap; Franck Broly
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.